JP2018522866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522866A5 JP2018522866A5 JP2017567060A JP2017567060A JP2018522866A5 JP 2018522866 A5 JP2018522866 A5 JP 2018522866A5 JP 2017567060 A JP2017567060 A JP 2017567060A JP 2017567060 A JP2017567060 A JP 2017567060A JP 2018522866 A5 JP2018522866 A5 JP 2018522866A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 21
- 239000013078 crystal Substances 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 20
- 239000000651 prodrug Substances 0.000 claims 19
- 229940002612 prodrug Drugs 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000004452 carbocyclyl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- 230000001568 sexual effect Effects 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 238000003419 tautomerization reaction Methods 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185334P | 2015-06-26 | 2015-06-26 | |
| US62/185,334 | 2015-06-26 | ||
| PCT/US2016/039312 WO2016210296A1 (en) | 2015-06-26 | 2016-06-24 | 4,6-pyrimidinylene derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522866A JP2018522866A (ja) | 2018-08-16 |
| JP2018522866A5 true JP2018522866A5 (enExample) | 2019-07-25 |
| JP6947651B2 JP6947651B2 (ja) | 2021-10-13 |
Family
ID=57585796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567060A Active JP6947651B2 (ja) | 2015-06-26 | 2016-06-24 | ４，６−ピリミジニレン誘導体およびこれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10695346B2 (enExample) |
| EP (1) | EP3313530B1 (enExample) |
| JP (1) | JP6947651B2 (enExample) |
| AU (1) | AU2016283105C1 (enExample) |
| WO (1) | WO2016210296A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3236959B1 (en) | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2017073065A1 (ja) * | 2015-10-28 | 2017-05-04 | 公益財団法人静岡県産業振興財団 | 新規抗がん薬 |
| CA3047404A1 (en) * | 2016-12-23 | 2018-06-28 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
| RU2020124136A (ru) * | 2017-12-22 | 2022-01-25 | Хиберселл, Инк. | Производные хроменопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы |
| MX2020006587A (es) * | 2017-12-22 | 2020-12-10 | Ravenna Pharmaceuticals Inc | Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa. |
| AU2018388406B2 (en) | 2017-12-22 | 2023-07-06 | HiberCell Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| CR20200503A (es) * | 2018-04-26 | 2020-12-17 | Pfizer | Inhibidores de cinasa dependientes de ciclina |
| EP3787629A4 (en) | 2018-05-02 | 2022-01-05 | Kinnate Biopharma Inc. | CYCLINE-DEPENDENT KINASE INHIBITORS |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| EP3813819A4 (en) * | 2018-06-29 | 2022-08-17 | Kinnate Biopharma Inc. | CYCLIN-DEPENDENT KINASE INHIBITORS |
| WO2020033823A1 (en) | 2018-08-10 | 2020-02-13 | Yale University | Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same |
| AU2019413694B2 (en) | 2018-12-28 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| TW202112784A (zh) * | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物 |
| CN113698391B (zh) * | 2020-05-21 | 2023-06-06 | 上海拓界生物医药科技有限公司 | 4-氨基嘧啶或2-氨基三嗪类化合物及其制备方法 |
| US20240109912A1 (en) * | 2020-12-21 | 2024-04-04 | Janssen Pharmaceutica Nv | Tricyclic pyrimidines as cyclin-dependent kinase 7 (cdk7) inhibitors |
| US20240245786A1 (en) * | 2020-12-23 | 2024-07-25 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of phosphatidylinositol-5-phosphate 4-kinase type 2 and uses thereof |
| US20240277852A1 (en) * | 2021-05-20 | 2024-08-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors and degraders of pip4k protein |
| JP2024534781A (ja) | 2021-08-18 | 2024-09-26 | ケモセントリックス，インコーポレイティド | Ｃｃｒ６阻害剤としてのアリールスルホニル（ヒドロキシ）ピペリジン |
| CA3229226A1 (en) | 2021-08-18 | 2023-02-23 | Chemocentryx, Inc. | Aryl sulfonyl compounds as ccr6 inhibitors |
| CN113698357A (zh) * | 2021-09-29 | 2021-11-26 | 守恒(厦门)医疗科技有限公司 | 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用 |
| CN113861130A (zh) * | 2021-09-29 | 2021-12-31 | 守恒(厦门)医疗科技有限公司 | 联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| WO2023227125A1 (zh) * | 2022-05-26 | 2023-11-30 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| CN116903587B (zh) * | 2023-06-01 | 2024-03-22 | 三峡大学 | 一种角鲨烯环氧酶抑制剂及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1205276A (en) * | 1915-03-29 | 1916-11-21 | Robert C Sharpe | Machine or instrument for cracking nuts. |
| DK1702917T3 (da) * | 2003-12-25 | 2017-11-13 | Nippon Shinyaku Co Ltd | Amidderivat og medicin |
| WO2007076474A1 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| EP2471529A3 (en) | 2006-09-05 | 2012-10-10 | Emory University | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof |
| NZ602832A (en) * | 2008-07-14 | 2014-04-30 | Gilead Sciences Inc | Fused heterocyclic hdac inhibitor compounds |
| KR20110120286A (ko) * | 2009-02-12 | 2011-11-03 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로환 유도체 |
| US9180127B2 (en) * | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| CN102406644A (zh) | 2010-09-20 | 2012-04-11 | 北大方正集团有限公司 | 芳基脲衍生物用于制备治疗移植排斥药物的新用途 |
| CN102408408A (zh) | 2010-09-20 | 2012-04-11 | 北大方正集团有限公司 | 具有抗肿瘤作用的芳基脲衍生物 |
| CN102406646B (zh) | 2010-09-20 | 2015-09-09 | 北大方正集团有限公司 | 芳基脲衍生物用于制备治疗移植排斥药物的用途 |
| CA2856291C (en) * | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| US9879003B2 (en) | 2012-04-11 | 2018-01-30 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN103242341B (zh) | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用 |
| CN104177363B (zh) | 2013-05-24 | 2018-06-05 | 江苏先声药业有限公司 | 双环杂环胺类Hedgehog信号通路抑制剂 |
| AU2014337122B2 (en) | 2013-10-18 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US10702527B2 (en) * | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| HK1254469A1 (zh) | 2015-06-26 | 2019-07-19 | Dana Farber Cancer Institute, Inc. | 稠合双环嘧啶衍生物及其用途 |
-
2016
- 2016-06-24 EP EP16815401.1A patent/EP3313530B1/en active Active
- 2016-06-24 AU AU2016283105A patent/AU2016283105C1/en not_active Ceased
- 2016-06-24 US US15/737,535 patent/US10695346B2/en active Active
- 2016-06-24 WO PCT/US2016/039312 patent/WO2016210296A1/en not_active Ceased
- 2016-06-24 JP JP2017567060A patent/JP6947651B2/ja active Active
-
2020
- 2020-06-11 US US16/899,412 patent/US20210315894A9/en not_active Abandoned